TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial

To date, there is no approved local therapeutic agent for the treatment of epistaxis due to hereditary hemorrhagic telangiectasia (HHT). Several case reports suggest the topical use of timolol. This monocentric, prospective, randomized, placebo-controlled, double-blinded, cross-over study investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Andorfer, Kornelia E. C., Zeman, Florian, Koller, Michael, Zeller, Judith, Fischer, René, Seebauer, Caroline T., Vielsmeier, Veronika, Bohr, Christopher, Kühnel, Thomas S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692661/
https://www.ncbi.nlm.nih.gov/pubmed/36365152
http://dx.doi.org/10.3390/pharmaceutics14112335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692661/
https://www.ncbi.nlm.nih.gov/pubmed/36365152
http://dx.doi.org/10.3390/pharmaceutics14112335

Ejemplares similares